Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance.

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products formulated using its Enhanze drug delivery technology. The company now estimates 2025 revenue will be between $1.

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year 2024 financial guidance The company also announced that it has entered into a new $250 million accelerated share repurchase program under the previously announced $750 million share repurchase program.